$FLNA

FILANA THERAPEUTICS, INC.

Filana Therapeutics is a clinical-stage biotechnology company headquartered in Austin, Texas. It develops drug candidates for central nervous system disorders, including Tuberous Sclerosis Complex-related epilepsy and other conditions associated with filamin A dysregulation or overexpression. Its scientific approach focuses on modulating filamin A, a scaffolding protein found in the brain and elsewhere in the body. Filana’s lead product candidate is simufilam, a proprietary oral small molecule designed in-house and studied for TSC-related epilepsy. The company is pursuing development of simufilam and exploring other potential indications. It owns or controls intellectual property related to simufilam and holds an exclusive worldwide license from Yale University to certain rights relevant to its development and commercialization. Filana outsources formulation, manufacturing and related activities to third parties, including clinical-grade drug supply. It discontinued its Alzheimer’s disease development program in the second quarter of 2025 and ended development of its SavaDx blood-based Alzheimer’s detection program in mid-2025.

0
1
0
$271K
—
Barry Richard
0%
See all $FLNA insider activity →

Schoen Eric purchased $8K of FLNA

Schoen Eric (Chief Financial Officer) purchased 20,000 shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.42 on 2026-11-16.

FLNA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning FLNA (FILANA THERAPEUTICS, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent FLNA coverage spans insider activity, financial news and earnings.

In the last 30 days, FLNA insiders filed 3 SEC Form 4 transactions — 3 purchases ($271K) and no sales. The most active reporter was Barry Richard, President & CEO, with 1 filing.

What's driving FLNA

  • Insider open-market buying can be read as confidence, but this is a modest-sized transaction and lacks a 10b5-1 plan disclosure.

    SEC EDGAR · Nov 18, 2026

  • Insider open-market purchase is modest in dollar terms and typically signals mild bullish sentiment, but is unlikely to drive near-term price action alone.

    SEC EDGAR · Nov 18, 2026

  • The filing is a modest insider open-market buy that may be read as confidence, but the dollar size is small and unlikely to drive price by itself.

    SEC EDGAR · Nov 18, 2026

  • Board addition may be viewed positively, modestly supporting the stock.

    SEC EDGAR 8-K · Nov 12, 2026

  • Minor governance update with limited immediate market effect.

    tradingview.com · Nov 11, 2026

AlphAI scores every news story that mentions FLNA with an AI model for sentiment and relevance, and aggregates insider trades from FILANA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $FLNA

Score
$FLNALowExec change· appointed

FILANA THERAPEUTICS, INC. (FLNA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board –Appointment brings leadership experience building and financing biopharma companies AUSTIN, Texas, November 11, 2026 (GLOBE NEWSWIRE) –– Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology

$FLNAMedEarnings

Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update – Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells 1 prov

A drug candidate restored a measure of how cells' powerhouses work in lab tests. Patient screening is expected by early 2027.

Filana Therapeutics (FLNA) announced preclinical research showing its drug candidate, simufilam, improved cellular stress responses and mitochondrial function in TSC2-deficient cells. The company plans to start a Phase 2a study for TSC-related epilepsy by Q1 2027. According to Yale researchers, simufilam reduced ATF4 expression by 37% and restored mitochondrial membrane potential. The findings suggest a potential mechanism distinct from mTOR inhibition.

Filana Therapeutics wins vacatur of class certification by 5th Circuit; case remanded

Filana Therapeutics won a vacatur of class certification in a securities suit by the Fifth Circuit, which found the Texas District Court misapplied legal standards. The case was remanded for further proceedings, with the appellate panel noting market inefficiency and meme-stock dynamics were not adequately considered. According to the Fifth Circuit, the district court did not properly evaluate evidence. Filana Therapeutics (FLNA) is the subject company.

FILANA THERAPEUTICS, INC. (FLNA): The United States Court of Appeals for the Fifth Circuit vacated the order of the U.S. District Court for the Western District of Texas granting class…

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 16, 2026, the United States Court of Appeals for the Fifth Circuit (the “Fifth Circuit”) vacated the order of the U.S. District Court for the Western District of Texas (the “Texas District Court”) granting class certification in the securities

Related tickers